Institutional Confidence in GTX-102 Boosts Outlook for Ultragenyx Pharmaceutical (RARE)

Analysts at Cantor Fitzgerald upgraded their rating on Ultragenyx Pharmaceutical Inc. to Overweight with a raised price target of $96, citing strong institutional confidence and favorable clinical trial design for GTX-102 in treating Angelman syndrome. Wedbush also maintained its Neutral stance but lowered the price target slightly.

By Muhammad Ali Khalid Fri, June 5, 2026 at 6:55 PM GMT+3 2 min read · Yahoo Finance · June 5, 2026, 15:55 UTC

Tickers: $RARE

Topics: biotech healthcare stock analysis

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC